Patents Examined by Delia Ramirez
  • Patent number: 10077436
    Abstract: Described herein are beta-glucosidase enzymes that have improved beta-glucosidase activity compared to a control beta-glucosidase enzyme. The improved beta-glucosidase enzymes are useful for converting a cellulosic biomass to fermentable sugars such as glucose. Also described are isolated polynucleotides that encode polypeptides having improved beta-glucosidase activity, expression cassettes for expressing the improved beta-glucosidase polypeptides, and cells, such as yeast cells, transformed with the expression cassettes.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: September 18, 2018
    Assignee: EDENIQ, INC.
    Inventors: Lan Sun, Ngim Muy Ung Ferrell, Deepak Singh, Jennifer Headman, Mei-Hua Chu, Michael Guerini, Sandra Jacobson
  • Patent number: 10066250
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 4, 2018
    Assignee: Codexis, Inc.
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • Patent number: 10053703
    Abstract: The present invention relates to methods for preparing patchoulol, ?-santalene, and sclareol in transgenic moss cells that include heterologous nucleic acid molecules encoding a polypeptide or synthase capable of using FPP or GGPP as a substrate. Methods for producing the transgenic moss cell, as well as the transgenic moss cell itself are also disclosed.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 21, 2018
    Assignees: UNIVERSITY OF COPENHAGEN, FIRMENICH SA
    Inventors: Henrik Simonsen, Dong-Fang Chen, Xin Zhan, Xiwu Pan, Brian Christopher King
  • Patent number: 10041137
    Abstract: The invention features a method of producing a high mannose glucocerebrosidase (hmGCB) which includes: providing a cell which is capable of expressing glucocerebrosidase (GCB), and allowing production of GCB having a precursor oligosaccharide under conditions which prevent the removal of at least one mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB, to thereby produce an hmGCB preparation. Preferably, the condition which prevents the removal of at least one mannose residue distal to the pentasaccharide core is inhibition of a class 1 processing mannosidase and/or a class 2 processing mannosidase. The invention also features an hmGCB preparation and methods of using an hmGCB preparation.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: August 7, 2018
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Carol M. Kinoshita, Prashant Mishra, Marianne Borowski, Peter Francis Daniel
  • Patent number: 10041135
    Abstract: Bacteriophage Insensitive Mutants (BIMs) of three Streptococcus thermophilus parent strains were generated and characterized for phage sensitivity, sedimentation rate, cell chain length, phage adsorption and CRISPR loci alterations. Several BIMs showed an altered sedimentation phenotype as well as an increase cell chain length, reduced phage sensitivity, reduced phage adsorption and 100% identity in three CRISPR loci. The results show that the derived BIMs have become phage-resistant through a mechanism other than CRISPR.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 7, 2018
    Assignee: DSM IP ASSETS B.V.
    Inventors: Roelof Hendrik Matthijs Kouwen, Pim Van Hee, Douwe Van Sinderen, Brian McDonnell, Jennifer Mahony
  • Patent number: 10035828
    Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 31, 2018
    Assignees: Novozymes A/S, Novozymes, Inc.
    Inventors: Kirk Schnorr, Randall Kramer
  • Patent number: 10035992
    Abstract: Presented herein are transposase enzymes and reaction conditions for improved fragmentation and tagging of nucleic acid samples, in particular altered transposases and reaction conditions which exhibit improved insertion sequence bias, as well as methods and kits using the same.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 31, 2018
    Assignee: ILLUMINA, INC.
    Inventors: Christian Gloeckner, Amirali Kia, Erin Bomati, Molly He, Haiying Li Grunenwald, Scott Kuersten, Trina Faye Osothprarop, Darin Haskins, Joshua Burgess, Anupama Khanna, Daniel Schlingman, Ramesh Vaidyanathan
  • Patent number: 10023888
    Abstract: Provided are a Corynebacterium glutamicum mutant that is resistant to high concentrations of L-glutamine, and a method of producing L-glutamine by using the mutant.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: July 17, 2018
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jin Nam Lee, Seung Hee Back, Jin Seok Sung, Tae Ho Song, Ha Dong Woo, Kyung Chang Lee, Jae Woo Jang
  • Patent number: 10023853
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: July 17, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10017802
    Abstract: The present invention relates to a method for the production of hyaluronic acid (HA) in Bacillus subtilis and Escherichia coli through plasmid vectors wherein the gene is under the control of strong promoter Pgrac, and a system for the selection of stable bacterial strains for the production of high levels of hyaluronic acid.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: July 10, 2018
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Vincenza Corsa, Alessandro Negro, Susanna Vaccaro, Luciano Messina
  • Patent number: 10006053
    Abstract: Gene targeting is a technique to introduce genetic change into one or more specific locations in the genome of a cell. For example, gene targeting can introduce genetic change by modifying, repairing, attenuating or inactivating a target gene or other chromosomal DNA. In one aspect, this disclosure relates to methods and compositions for gene targeting with high efficiency in a cell. This disclosure also relates to methods of treating or preventing a genetic disease in an individual in need thereof. Further disclosed are chimeric nucleases and vectors encoding chimeric nucleases.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 26, 2018
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Matthew Porteus
  • Patent number: 9999238
    Abstract: Provided herein are variants of Buttiauxella sp. phytases that may be used in industrial applications including methods for starch liquefaction, alcohol fermentations and for enhancing phosphate digestion in foods and animal feeds.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 19, 2018
    Assignee: DANISCO US INC
    Inventors: Oliver Kensch, Klaus Schulze Pellengahr, Birgitta Leuthner, Jayarama K Shetty, Michael J. Pepsin, Soeren Dalsgaard, Mai Faurschou Isaksen
  • Patent number: 10000782
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to have reduced levels or activity of one or more alcohol dehydrogenases or aldehyde reductase thereby increasing the production of vanillin or vanillin beta-D-glucoside.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 19, 2018
    Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Esben Halkjaer Hansen, Swee Chuang Lim Hallwyl, Klavs Riishede Hansen
  • Patent number: 9994882
    Abstract: Provided are a Corynebacterium glutamicum mutant that is resistant to high concentrations of L-glutamine, and a method of producing L-glutamine by using the mutant.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: June 12, 2018
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jin Nam Lee, Seung Hee Back, Jin Seok Sung, Tae Ho Song, Ha Dong Woo, Kyung Chang Lee, Jae Woo Jang
  • Patent number: 9988688
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: June 5, 2018
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 9982244
    Abstract: Presented herein are recombinases for improved recombinase-mediated amplification of nucleic acids, such as a PCR-library having single-stranded adapter regions, on a patterned flow cell surface for improved cluster amplification, as well as methods and kits using the same.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: May 29, 2018
    Assignee: ILLUMINA CAMBRIDGE LIMITED
    Inventors: Erin Bomati, Matthew William Kellinger, Jonathan Mark Boutell
  • Patent number: 9970031
    Abstract: A method for producing a dicarboxylic acid is provided. A dicarboxylic acid is produced by culturing a bacterium having a dicarboxylic acid-producing ability, which has been modified so that the expression of one or more of the yeeA gene, ynfM gene, yjjP gene, and yjjB gene is increased, in a medium, and collecting the dicarboxylic acid from the medium.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: May 15, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yoshihiko Hara, Keita Fukui, Daiki Yahagi
  • Patent number: 9957490
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 1, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 9951318
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 24, 2018
    Assignee: Codexis, Inc.
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
  • Patent number: 9890404
    Abstract: The present invention relates to a putrescine-producing microorganism and a method for producing putrescine using the same. To be more specific, the present invention is directed to a microorganism given the ability to produce putrescine which is generated by blocking a biosynthetic pathway from ornithine to arginine, increasing the intracellular level of glutamate, enhancing the biosynthetic pathway of ornithine from glutamate, and introducing extracellular ornithine decarboxylase; and a method for producing putrescine by using the microorganism.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: February 13, 2018
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Hyang Choi, Kyoung Min Lee, Min Sun Kang, Sung Hoo Jhon, Hye Won Um, Su Jin Choi, Han Won Lee, Soo An Shin